The FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms should they feel an attack coming on.
Michael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive of New York-based venture capitalist Apple Tree Partners.
bluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy (CALD), showing that it continues to work in the long-te
